Article Sidebar
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Clinical efficacy and safety of xiaoyao pill in post-stroke depression: A systematic review and meta-analysis of randomized controlled trials
Abstract
Purpose: To review the efficacy and safety of the xiaoyao pill in the treatment of post-stroke depression.
Methods: A meta-analysis was conducted using eligible studies found in relevant electronic databases [e.g., Embase, Baidu Scholar, Google Scholar, PubMed, Cochrane Library, Science and Technology Periodical Database (VIP) in China, Chinese Biomedical Database, Wanfang, and China National Knowledge Infrastructure]. Statistical analyses were performed using Stata (version 12) and Review (version 5.3).
Results: Eleven articles with a total of 1007 patients were included in this study. Overall, the results of the published studies show that xiaoyao pill combined with conventional drug therapy increases clinical response by 20 %. In contrast, Hamilton Depression Scale score and Scandinavian Stroke Scale score were significantly (p < 0.05) lower in xiaoyao pill treatment group than in control group. As an adjuvant therapy, xiaoyao pill reduces potential adverse reactions, suggesting that it can be used as a supplementary therapy in the management of post-stroke depression patients.
Conclusion: The review and meta-analysis provide preliminarily proof that xiaoyao pill can improve the clinical symptoms of patients with post-stroke depression and has a higher safety profile than conventional drug therapy. These findings suggest that xiaoyao pill can be used as an alternative or complementary drug for the management of post-stroke depression.
